NCT05975619View on ClinicalTrials.gov

A Prospective Imaging Study of the Integrated TrueBeam-HyperSight CBCT System

NAActive, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 29, 2023

Primary Completion Date

March 24, 2025

Study Completion Date

April 30, 2026

Conditions
Head and Neck CancerThoracic CancerAbdominal CancerPelvic Cancer
Interventions
DEVICE

HyperSight imaging

Subjects are scheduled for 1 to 5 HyperSight imaging sessions, which will occur on the same days as their standard clinical visits during planning and treatment delivery. A total of 5 to 10 HyperSight CBCT images will be acquired over all imaging sessions.

Trial Locations (1)

44106

University Hospitals Cleveland Medical Center, Cleveland

All Listed Sponsors
lead

Varian, a Siemens Healthineers Company

INDUSTRY

NCT05975619 - A Prospective Imaging Study of the Integrated TrueBeam-HyperSight CBCT System | Biotech Hunter | Biotech Hunter